Report: Eli Lilly Said to Play Down Risk

Monday, 18 Dec 2006 | 2:20 PM ET

Eli Lilly has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its Web site Sunday, citing internal documents from the drug maker and e-mail messages of its managers.

Lilly Defends Zyprexa Allegations
Eli Lilly fires back at The New York Times after the paper ran two unfavorable stories about the company's lucrative Schizophrenia drug, Zyprexa. Mike Huckman, CNBC Pharmaceuticals Reporter, has the details.

The documents, obtained from a lawyer for mentally ill patients, show Lilly executives kept data from doctors about the drug's tendencies to promote obesity and boost blood sugar, the newspaper said.

Zyprexa is Lilly's best-selling product. With sales of $4.2 billion last year, about 2 million people worldwide were taking the drug.

Thirty percent of patients taking Zyprexa gain 22 pounds or more after a year on the drug, and some patients have reported putting on more than 100 pounds, according to information published by Lilly. But the internal documents, which cover the period from 1995 to 2004, show Lilly feared sales would be hurt if the company was open with doctors the drug's side effects, the paper said.

Lilly denied there was a connection between the drug and diabetes on Friday in a written response to questions about the documents, according to The New York Times. The drug maker said the documents had been taken out of context, the newspaper said.

  Price   Change %Change


Contact U.S. News


    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • The U.S. Supreme Court is hearing arguments from Argentina and hedge fund creditor NML Capital over refusal of bond payment, reports CNBC's Kate Kelly.

  • This bull market has room to go, but expect a lot of volatility over the next few months, says Jim Lacamp, UBS senior VP of investments and portfolio manager, explaining why investors need to be careful after last week's market bounce back.

  • Henry Blodget, Business Insider editor-in-chief & CEO, shares his thoughts on Nike's apparent move away from wearable tech after a CNET report that says the company fired the majority of its FuelBand team.